Also referred to as mitogen-activated protein kinase phosphatase 2 (MKP-2), its low expression or downregulation is linked to aggressive tumor phenotypes, metastasis, and poor prognosis [32–34] [35], and an enhancer of chemotherapy efficacy [36–38]. The gene discussed is DUSP4; the disease is neoplasm.